Department of Pathology and Immunology, University of Geneva, Switzerland.
Semin Immunol. 2011 Dec;23(6):438-45. doi: 10.1016/j.smim.2011.08.003. Epub 2011 Sep 3.
Accumulating evidence indicates that IL-27, a member of the IL-12 family of cytokines, alleviates the severity of autoimmune diseases in both mice and men. The IL-27-induced activation of signal transducer and activator of transcription (Stat)1 and Stat3 promotes the generation of IL-10- producing type 1 regulatory T (Tr1) cells that inhibit effector T cells. In addition, IL-27 also suppresses the development of pathogenic IL-17-producing CD4(+) T cells (T(H)17) cells suggesting that pharmacological manipulations of IL-27 signaling pathway could be exploited therapeutically in regulating tissue inflammation. Here, we review how IL-27 controls inflammation through the regulation of Tr1 and T(H)17 responses.
越来越多的证据表明，白细胞介素-27（IL-27）作为白细胞介素-12 家族细胞因子的一员，可减轻小鼠和人类自身免疫性疾病的严重程度。IL-27 诱导信号转导和转录激活因子（Stat）1 和 Stat3 的激活，促进产生白细胞介素-10（IL-10）的 1 型调节性 T（Tr1）细胞，从而抑制效应 T 细胞。此外，IL-27 还抑制致病性产生白细胞介素-17（IL-17）的 CD4+T 细胞（T(H)17）的发育，这表明对 IL-27 信号通路的药理学操作可以在调节组织炎症中得到利用。在这里，我们回顾了 IL-27 通过调节 Tr1 和 T(H)17 反应来控制炎症的机制。
